← Back to Search

VNS for Bipolar Depression (RECOVER Trial)

N/A
Recruiting
Led By Charles Conway, MD
Research Sponsored by LivaNova
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
The patient must be in a major depressive disorder (MDD) episode for ≥ two years or have had at least four episodes of MDD, including the current episode.
The patient must be in a major depressive disorder (MDD) episode for ≥ two years or have had at least four episodes of MDD, including the current episode.
Timeline
Screening 6 weeks
Treatment 60 months
Follow Up 1 month

Summary

This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.

Who is the study for?
This trial is for adults with treatment-resistant depression, which means they've tried at least four different treatments without success. They should be currently in a major depressive episode that's lasted for two years or more, or have had at least four episodes of major depression. Participants must not change their medications for four weeks before getting the VNS device and can't join if they have certain cognitive disorders, a history of rapid cycling bipolar disorder, schizophrenia, other psychotic disorders, or current suicidal thoughts.
What is being tested?
The study is testing whether using Vagus Nerve Stimulation (VNS) as an additional treatment helps reduce symptoms of severe depression compared to no stimulation control after one year. Patients are randomly assigned to either receive active VNS Therapy or be part of the control group that does not receive stimulation.
What are the potential side effects?
Possible side effects from Vagus Nerve Stimulation may include voice changes due to nerve irritation, coughing, sore throat, shortness of breath, tingling sensation in the skin and difficulty swallowing. These side effects vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been in a major depressive episode for over two years or have had at least four episodes.
Select...
I have been in a major depressive episode for over two years or have had at least four episodes.
Select...
I have been diagnosed with major depression twice in the last 45 days.

Timeline

Screening ~ 6 weeks
Treatment ~ 60 months
Follow Up ~1 month
This trial's timeline: 6 weeks for screening, 60 months for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess all Adverse Events
Clinical Global Impressions Scale - Improvement (CGI-I) Response
Montgomery Åsberg Depression Rating Scale (MADRS) Duration of Remission
+8 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: ActiveActive Control1 Intervention
Group will have VNS activated 2 weeks post implant.
Group II: ControlPlacebo Group1 Intervention
Group will be implanted with VNS but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.

Find a Location

Logistics

Other reimbursement is provided

Other forms of reimbursement are provided for this trial.

Who is running the clinical trial?

LivaNovaLead Sponsor
65 Previous Clinical Trials
24,287 Total Patients Enrolled
Charles Conway, MDPrincipal InvestigatorWashington University School of Medicine
5 Previous Clinical Trials
1,061 Total Patients Enrolled

Media Library

Active Clinical Trial Eligibility Overview. Trial Name: NCT03887715 — N/A
Bipolar Depression Research Study Groups: Active, Control
Bipolar Depression Clinical Trial 2023: Active Highlights & Side Effects. Trial Name: NCT03887715 — N/A
Active 2023 Treatment Timeline for Medical Study. Trial Name: NCT03887715 — N/A
Bipolar Depression Patient Testimony for trial: Trial Name: NCT03887715 — N/A
~2558 spots leftby Feb 2028